Dekeyser Manon, de Goër de Herve Marie-Ghislaine, Hendel-Chavez Houria, Lhotte Romain, Scriabine Ivan, Bargiel Karen, Boutin Emmanuelle, Herr Florence, Taupin Jean-Luc, Taoufik Yassine, Durrbach Antoine
INSERM 1186, Gustave Roussy Institute, Villejuif, France.
Paris-Saclay University, Paris, France.
Kidney Int Rep. 2024 May 7;9(8):2498-2513. doi: 10.1016/j.ekir.2024.04.070. eCollection 2024 Aug.
BK polyomavirus-associated nephropathy (BKPyVAN) is a significant complication in kidney transplant recipients (KTRs), associated with a higher level of plasmatic BK polyomavirus (BKPyV) replication and leading to poor graft survival.
We prospectively followed-up with 100 KTRs with various degrees of BKPyV reactivation (no BKPyV reactivation, BKPyV-DNAuria, BKPyV-DNAemia, and biopsy-proven BKPyVAN [bp-BKPyVAN], 25 patients per group) and evaluated BKPyV-specific T cell functionality and phenotype.
We demonstrate that bp-BKPyVAN is associated with a loss of BKPyV-specific T cell proliferation, cytokine secretion, and cytotoxic capacities. This severe functional impairment is associated with an overexpression of lymphocyte inhibitory receptors (programmed cell death 1 [PD1], cytotoxic T lymphocyte-associated protein 4, T cell immunoreceptor with Ig and ITIM domains, and T cell immunoglobulin and mucin domain-containing-3), highlighting an exhausted-like phenotype of BKPyV-specific CD4 and CD8 T cells in bp-BKPyVAN. This T cell dysfunction is associated with low class II donor-recipient human leukocyte antigen (HLA) divergence. In contrast, in the context of higher class II donor-recipient HLA (D/R-HLA) divergence, allogeneic CD4 T cells can provide help that sustains BKPyV-specific CD8 T cell responses. , allogeneic HLA-mismatched CD4 T cells rescue BKPyV-specific CD8 T cell responses.
Our findings suggest that in KTRs, allogeneic CD4 T cells can help to maintain an effective BKPyV-specific CD8 T cell response that better controls BKPyV replication in the kidney allograft and may protect against BKPyVAN.
BK多瘤病毒相关性肾病(BKPyVAN)是肾移植受者(KTRs)的一种严重并发症,与血浆BK多瘤病毒(BKPyV)复制水平升高相关,并导致移植肾存活率低下。
我们对100例有不同程度BKPyV再激活的KTRs(无BKPyV再激活、BKPyV-DNA尿症、BKPyV-DNA血症和活检证实的BKPyVAN [bp-BKPyVAN],每组25例患者)进行前瞻性随访,并评估BKPyV特异性T细胞功能和表型。
我们证明bp-BKPyVAN与BKPyV特异性T细胞增殖、细胞因子分泌和细胞毒性能力丧失有关。这种严重的功能损害与淋巴细胞抑制性受体(程序性细胞死亡1 [PD1]、细胞毒性T淋巴细胞相关蛋白4、具有Ig和ITIM结构域的T细胞免疫受体以及含T细胞免疫球蛋白和粘蛋白结构域-3)的过表达有关,突出了bp-BKPyVAN中BKPyV特异性CD4和CD8 T细胞的耗竭样表型。这种T细胞功能障碍与II类供体-受体人类白细胞抗原(HLA)差异低有关。相比之下,在II类供体-受体HLA(D/R-HLA)差异较高的情况下,同种异体CD4 T细胞可以提供帮助,维持BKPyV特异性CD8 T细胞反应。 ,同种异体HLA不匹配的CD4 T细胞可挽救BKPyV特异性CD8 T细胞反应。
我们的研究结果表明,在KTRs中,同种异体CD4 T细胞可以帮助维持有效的BKPyV特异性CD8 T细胞反应,更好地控制肾移植中BKPyV的复制,并可能预防BKPyVAN。